Nonsteroidal mineralocorticoid receptor antagonists and cardiovascular events in type 2 diabetes: a retrospective study
European Heart Journal - Cardiovascular Pharmacotherapy · 2025
DOI: 10.1093/ehjcvp/pvaf048 ↗Kurz gefasst
Vergleichsstudie in der Zeitschrift European Heart Journal - Cardiovascular Pharmacotherapy, 2025. Verfasst von Yi-Hsien Chen und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Family Medicine, Shin-Kong Wu Ho-Su Memorial Hospital, No. 95, Wen-Chang Rd, Shih-Lin Dist., Taipei 11101, Taiwan. Hauptthemen laut MEDLINE: Diabetes Mellitus, Type 2, Mineralocorticoid Receptor Antagonists, Eplerenone, Spironolactone. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 30 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Shin Kong Wu Ho-Su Memorial Hospital.
Themen: Diabetes mellitus
Abstract (Originalsprache)
Aims
Nonsteroidal mineralocorticoid receptor antagonists such as finerenone mitigate cardiorenal risks in patients with type 2 diabetes mellitus (T2DM). Real-world evidence comparing finerenone with spironolactone and eplerenone remains limited. This study aimed to evaluate the cardiovascular outcomes in T2DM patients treated with finerenone vs. spironolactone or eplerenone using real-world data. Methods and results A retrospective cohort analysis was conducted using the TriNetX US Collaborative Network database. Adult patients with T2DM who were newly prescribed finerenone, spironolactone, or eplerenone were included (2021–2024). One-to-one propensity score matching was applied to eligible participants, resulting in 2957 finerenone users matching with spironolactone users and 1603 finerenone users matching with eplerenone users. Cardiovascular outcomes, including major adverse cardiovascular events (MACEs), heart failure, and mortality, were assessed over 24 months of follow-up. Hazard ratios (HRs) with 95% confidence intervals (CI) were calculated using Cox regression models. Finerenone users had significantly lower rates of MACE compared with spironolactone users (HR: 0.53, 95% CI: 0.43–0.66) and eplerenone (HR: 0.66, 95% CI: 0.50–0.87). Mortality was also reduced with finerenone vs. spironolactone (HR: 0.45, 95% CI: 0.35–0.57) and eplerenone (HR: 0.56, 95% CI: 0.41–0.75). Heart failure events were fewer with finerenone than with spironolactone (HR: 0.70, 95% CI: 0.55–0.90) and eplerenone (HR: 0.70, 95% CI: 0.50–0.99). Differences in acute myocardial infarction and stroke rates were not statistically significant.
Conclusion
Finerenone demonstrated superior cardiovascular outcomes compared with spironolactone and eplerenone in patients with T2DM with significant reductions in MACE, mortality, and heart failure events.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Family Medicine, Shin-Kong Wu Ho-Su Memorial Hospital, No. 95, Wen-Chang Rd, Shih-Lin Dist., Taipei 11101, Taiwan.
- Division of Nephrology, Department of Internal Medicine, Shin-Kong Wu Ho-Su Memorial Hospital, No. 95, Wen-Chang Rd, Shih-Lin Dist., Taipei 11101, Taiwan.
- Department of Medicine, Fu Jen Catholic University, New Taipei City 242062, Taiwan.
- Department of Healthcare Management, National Taipei University of Nursing and Health Sciences, Taipei 112303, Taiwan.
- Division of Nephrology, Department of Internal Medicine, Hsin-Jen Hospital, New Taipei City 242009, Taiwan.
ORCID-Profile: Ming-Hsien Tsai
Förderung
- Shin Kong Wu Ho-Su Memorial Hospital
Zitieren
APA
Chen, Y. H., Fang, Y. W., Chen, M. T., Liou, H. H., & Tsai, M. H. (2025). Nonsteroidal mineralocorticoid receptor antagonists and cardiovascular events in type 2 diabetes: a retrospective study. European Heart Journal - Cardiovascular Pharmacotherapy. https://doi.org/10.1093/ehjcvp/pvaf048
Vancouver
Chen YH, Fang YW, Chen MT, Liou HH, Tsai MH. Nonsteroidal mineralocorticoid receptor antagonists and cardiovascular events in type 2 diabetes: a retrospective study. European Heart Journal - Cardiovascular Pharmacotherapy. 2025. doi:10.1093/ehjcvp/pvaf048
BibTeX
@article{Chen2025,
author = {Chen, Yi-Hsien and Fang, Yu-Wei and Chen, Mon-Ting and Liou, Hung-Hsiang and Tsai, Ming-Hsien},
title = {Nonsteroidal mineralocorticoid receptor antagonists and cardiovascular events in type 2 diabetes: a retrospective study},
journal = {European Heart Journal - Cardiovascular Pharmacotherapy},
year = {2025},
doi = {10.1093/ehjcvp/pvaf048}
}
EUVIMED